scholarly journals The Anticancer Efficacy of Plasma-Oxidized Saline (POS) in the Ehrlich Ascites Carcinoma Model In Vitro and In Vivo

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 932
Author(s):  
Walison Augusto Silva Brito ◽  
Eric Freund ◽  
Thiago Daniel Henrique do Nascimento ◽  
Gabriella Pasqual-Melo ◽  
Larissa Juliani Sanches ◽  
...  
Keyword(s):  
Peritoneal Carcinomatosis ◽  
Anticancer Agent ◽  
Ex Vivo ◽  
Ehrlich Ascites Carcinoma ◽  
Malignant Ascites ◽  
Anticancer Efficacy ◽  
Ehrlich Ascites ◽  
Physical Plasma

Cold physical plasma, a partially ionized gas rich in reactive oxygen species (ROS), is receiving increasing interest as a novel anticancer agent via two modes. The first involves its application to cells and tissues directly, while the second uses physical plasma-derived ROS to oxidize liquids. Saline is a clinically accepted liquid, and here we explored the suitability of plasma-oxidized saline (POS) as anticancer agent technology in vitro and in vivo using the Ehrlich Ascites Carcinoma (EAC) model. EAC mainly grows as a suspension in the peritoneal cavity of mice, making this model ideally suited to test POS as a putative agent against peritoneal carcinomatosis frequently observed with colon, pancreas, and ovarium metastasis. Five POS injections led to a reduction of the tumor burden in vivo as well as in a decline of EAC cell growth and an arrest in metabolic activity ex vivo. The treatment was accompanied by a decreased antioxidant capacity of Ehrlich tumor cells and increased lipid oxidation in the ascites supernatants, while no other side effects were observed. Oxaliplatin and hydrogen peroxide were used as controls and mediated better and worse outcomes, respectively, with the former but not the latter inducing profound changes in the inflammatory milieu among 13 different cytokines investigated in ascites fluid. Modulation of inflammation in the POS group was modest but significant. These results promote POS as a promising candidate for targeting peritoneal carcinomatosis and malignant ascites and suggest EAC to be a suitable and convenient model for analyzing innovative POS approaches and combination therapies.

scholarly journals Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent

Blood ◽  
2016 ◽  
Vol 128 (14) ◽  
pp. 1845-1853 ◽  
Author(s):  
Michael Xiang ◽  
Haesook Kim ◽  
Vincent T. Ho ◽  
Sarah R. Walker ◽  
Michal Bar-Natan ◽  
...  
Keyword(s):  
Gene Expression ◽  
Retrospective Study ◽  
Human Plasma ◽  
Patient Outcomes ◽  
Anticancer Agent ◽  
Plasma Concentrations ◽  
Anticancer Efficacy ◽  
Key Points

Key PointsThe FDA-approved drug atovaquone is a novel, clinically available inhibitor of STAT3 at standard human plasma concentrations. Atovaquone shows anticancer efficacy in vitro, in vivo, and in a retrospective study of AML patient outcomes after atovaquone treatment.

scholarly journals In vitro and in vivo evaluation of antitumor activity of methanolic extract of Argyreia nervosa leaves on Ehrlich ascites carcinoma

2015 ◽  
Vol 10 (2) ◽  
pp. 399
Author(s):  
Bhawna Sharma ◽  
Isha Dhamija ◽  
Sandeep Kumar ◽  
Hema Chaudhary
Keyword(s):  
Antitumor Activity ◽  
Solid Tumor ◽  
Methanolic Extract ◽  
Ehrlich Ascites Carcinoma ◽  
Ehrlich Ascites ◽  
Wide Range ◽  
Antioxidant Parameters ◽  
Argyreia Nervosa

<p>The herb of importance like <em>Argyreia nervosa</em> has shown wide range of pharmacological activities. Its methanolic extract of <em>A. nervosa</em> has been explored against Ehrlich ascites carcinoma (EAC) induced liquid and solid tumor in mice. Liquid and solid tumors were induced by intraperitoneal and subcutaneous transplantation of EAC cells in Balb/C mice. Significant and dose dependant results are observed when the mice are sacrificed on 15<sup>th</sup> day for estimation of tumor proliferation, hematological, biochemical and hepatic antioxidant parameters. Mean survival time (days) was increased to 36.5 from 20.5 extract treated mice. The extract also showed a decrease (p&lt;0.001) in body weight and percentage reduction in tumor volume respectively when it was evaluated in solid tumor induced mice for a period of 30 days.  From the result it was concluded that the extract has as a potent antitumor activity and that is comparable to 5-fluorouracil.</p><p> </p>

THE ENZYMIC FORMATION OF 6-(METHYLMERCAPTO)PURINE RIBONUCLEOSIDE 5′-PHOSPHATE

1966 ◽  
Vol 44 (2) ◽  
pp. 229-245 ◽  
Author(s):  
Ian C. Caldwell ◽  
J. Frank Henderson ◽  
A. R. P. Paterson
Keyword(s):  
Tumor Cells ◽  
Blood Cells ◽  
Intraperitoneal Injection ◽  
Ehrlich Ascites Carcinoma ◽  
Carcinoma Cells ◽  
Ehrlich Ascites ◽  
Mouse Tissues ◽  
Enzymatic Methods

6-(Methylmercapto)purine ribonucleoside (Me6MPR) is efficiently phosphorylated in mouse tissues and in Ehrlich ascites carcinoma cells in vivo; tumor cells in vitro and cell-free extracts of the tumor also phosphorylate this analogue ribonucleoside. The product of this reaction has been identified by chemical and enzymatic methods and by its chromatographic behaviour as Me6MPR 5′-phosphate. The evidence presented in this report indicates that no other major metabolites of Me6MPR are formed.The phosphorylation of Me6MPR by cell-free tumor extracts requires ATP and Mn2+ (or Mg2+), and evidence is presented that the reaction is probably mediated by adenosine kinase.Me-14C-6MPR is rapidly taken up by most mouse tissues following its intraperitoneal injection. Forty minutes after injection of the labeled drug, the highest levels of radioactivity were found in intestine, liver, blood cells, lung, and spleen, in descending order; virtually no radioactivity was found in brain tissue or in blood plasma.

scholarly journals Betulin-3,28-diphosphate as a Component of Combination Cytostatic Drugs for the Treatment of Ehrlich Ascites Carcinoma In Vitro and In Vivo Experiments

2018 ◽  
Vol 86 (2) ◽  
pp. 17 ◽  
Author(s):  
Olga Vorobyova ◽  
Olga Deryabina ◽  
Darina Malygina ◽  
Nadezhda Plotnikova ◽  
Anna Solovyeva ◽  
...  
Keyword(s):  
Ehrlich Ascites Carcinoma ◽  
Cytostatic Drugs ◽  
In Vivo Experiments ◽  
Ehrlich Ascites

scholarly journals The Anti-Tumoral Effects of Wolfberry (Lycium barbarum) on Experimentally Induced Ehrlich Ascites Carcinoma in Mice

Proceedings ◽  
2019 ◽  
Vol 40 (1) ◽  
pp. 38
Author(s):  
Uçar ◽  
Ülger ◽  
AL ◽  
Nisari ◽  
Karatoprak
Keyword(s):  
Histopathological Examination ◽  
Apoptotic Cell ◽  
Ehrlich Ascites Carcinoma ◽  
Lycium Barbarum ◽  
In Vitro Techniques ◽  
Cell Percentage ◽  
Ehrlich Ascites ◽  
Eat Cells

Wolfberry (Lycium barbarum) shows strengthen immune system, antioxidant and anticancerogenic effect. In this research, the effects of Wolfberry's extract fractions, cultivated in Kayseri, investigated on Ehrlich ascites tumor (EAT) using in vivo and in vitro techniques. For in vivo study, 200 mg/kg fractions of Wolfberry extract (above and below 50 kDa) were injected ip to EAT injected Balb/C mice. EAT cells were also cultured in the presence of Wolfberry's extract fractions (1500, 2000 µg/ml) to examine cell vitality and apoptosis using the Muse Cell Analyzer. Histopathological examination of intra-abdominal organs showed that there were decrease in the EAT cells adherence in the Wolfberry applied tissue groups when compared to the control. According to in vitro results, the both extract fractions (above and below 50 kDa) increased apoptosis in cancer cells. However, total apoptotic cell percentage was higher and statistically significant in groups above 50 kDa (1500, 2000 mg/ml) (p < 0.05). Previous literature and the results of the present study reveal that the consumption of wolfberry—which is also produced in Turkey—might be effective in preventing the formation of cancer and the deceleration of its progress.

THE ROLE OF THIOL GROUPS IN THE DEVELOPMENT OF RADIATION DAMAGE IN THYMOCYTES AND EHRLICH ASCITES CARCINOMA CELLS

1964 ◽  
Vol 42 (12) ◽  
pp. 1717-1727 ◽  
Author(s):  
J. F. Scaife
Keyword(s):  
Ehrlich Ascites Carcinoma ◽  
Carcinoma Cells ◽  
Irradiation Damage ◽  
Thiol Groups ◽  
Protein Thiol ◽  
Ehrlich Ascites ◽  
X Irradiation ◽  
The Difference

The effect of 800–1000 rads of X-irradiation on the thiol content of thymocytes and Ehrlich ascites carcinoma cells has been compared. Four hours after irradiation there was a decrease in the non-protein thiol (NP.SH) content of thymus and thymocytes but no change in ascites cells. In both cells the main NP.SH compound was glutathione. There was no significant effect of irradiation on the protein thiol (P.SH) content of thymus or ascites cells, but there was a slight decrease in P.SH in thymocytes after 4 hours incubation. Isolated thymus nuclei showed an immediate small decrease in P.SH content following 800 rads in vitro. Nuclei isolated from rat thymus 1 hour after 1000 rads in vivo showed an increase in the SH content of the globulin fraction and a decrease in the SH content of the nucleohistones. The total SH content of thymocytes and ascites cells was reduced by slow diffusion of H2O2into the cell suspension, but no effect of prior irradiation on this decrease of SH was found. Inhibition of catalase in vivo and in vitro did not produce any of the morphological signs of irradiation damage in thymocytes. There was no effect of irradiation on the copper content of thymus, thymocytes, or ascites cells. The ratio of NP.SH/P.SH is higher in thymocytes than in ascites cells, but, allowing for the difference in cell size, the overall total thiol concentration was the same. Anoxia produced only a small increase in NP.SH content in both cells and a small and doubtful increase in P.SH. It is concluded that, if thiol groups are involved in cell sensitivity to radiation, only a small fraction of the total SH groups are involved at critical sites.

scholarly journals In vitro and in vivo evaluation of anisomycin against Ehrlich ascites carcinoma

2013 ◽  
Vol 29 (6) ◽  
pp. 2227-2236 ◽  
Author(s):  
PENGTAO YOU ◽  
FEIYUE XING ◽  
JIE HUO ◽  
BAOYU WANG ◽  
JINGFANG DI ◽  
...  
Keyword(s):  
Ehrlich Ascites Carcinoma ◽  
In Vivo Evaluation ◽  
Ehrlich Ascites

Evaluation of Cisplatin Combined with Ondansetron in Ehrlich Ascites Carcinoma in Vitro and in Vivo

2000 ◽  
Vol 86 (2) ◽  
pp. 153-156 ◽  
Author(s):  
Osama Ahmed Badary ◽  
Sahar Moustafa Sharaby ◽  
Sanaa Abd El-Baky Kenawy ◽  
Ezz El-Deen El-Denshary ◽  
Farid Mohamed Ahmed Hamada
Keyword(s):  
Antitumor Activity ◽  
Ehrlich Ascites Carcinoma ◽  
Host Tissue ◽  
Nausea And Vomiting ◽  
Single Treatment ◽  
Blood Cell Count ◽  
Ehrlich Ascites ◽  
Eac Cells

Aims and background Nausea and vomiting occur in the majority of patients receiving cisplatin (CDDP) chemotherapy. Ondansetron, a new 5-HT3 receptor antagonist, has been used effectively to control CDDP-induced nausea and vomiting. This study examined the potential of ondansetron to interfere with CDDP antitumor activity and toxicity in Ehrlich ascites carcinoma (EAC). Methods The influence of ondansetron on CDDP cytotoxicity was evaluated using EAC cells in culture. In addition, the influence of ondansetron pretreatment on CDDP-induced antitumor activity and host tissue toxicity was studied in EAC-bearing mice. Results Ondansetron (0.25 μM) enhanced CDDP (0–32 μM) cytotoxicity against EAC cells in vitro. In EAC-bearing mice ondansetron (0.2 mg/kg, ip) administered 1 h before CDDP (7 mg/kg, ip) did not modify the antitumor activity of CDDP. CDDP (7 mg/kg, ip) single treatment induced significant increases in blood urea nitrogen (2-fold) and serum creatinine (2.5-fold) and significant decreases in hematocrit (25%) and white blood cell count (39%) compared to saline treatment. Mice receiving ondansetron 1 h before CDDP showed no significant enhancement of CDDP-induced nephrotoxicity or myelosuppression compared to those pretreated with saline receiving the same dose of CDDP. Conclusions This study suggests that the use of ondansetron to control CDDP-induced nausea and vomiting does not affect CDDP antitumor efficacy.

Sign in / Sign up

Export Citation Format

Share Document